{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:50:19Z","timestamp":1781103019609,"version":"3.54.1"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>[<jats:sup>44<\/jats:sup>Sc]Sc-PSMA-617 with 3.9-hour half-life, in vitro and in vivo characteristics similar to [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 and possibility of delayed imaging after 24 hours or later, implies it to be advantageous than [<jats:sup>68<\/jats:sup> Ga]Ga-PSMA-617 for pretherapeutic dosimetric assessment for [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 in metastatic castration-resistant prostate carcinoma (mCRPC) patients. In this study, we investigated biodistribution and radiation exposure to normal organs with [<jats:sup>44<\/jats:sup>Sc]Sc-PSMA-617 in mCRPC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Five mCRPC patients (mean age, 69 years) enrolled for [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 therapy were injected with 40\u201362 MBq [<jats:sup>44<\/jats:sup>Sc]Sc-PSMA-617 intravenously; Siemens Biograph 2 PET\/CT system was used to acquire dynamic PET data (30 minutes) in list mode over the abdomen, followed by the collection of static PET\/CT images (skull to mid-thigh) at 45 minutes, 2 and approximately 20 hours postinjection. Time-dependent changes in percentage activity in source organs (kidneys, bladder, salivary glands, small intestine, liver, spleen, and whole body) were determined. Bone marrow and urinary bladder contents residence time were also calculated. Source organs residence time, organ-absorbed doses, and effective doses were determined using OLINDA\/EXM software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Physiological tracer uptake was seen in kidneys, liver, spleen, small intestine, urinary bladder, and salivary glands and in metastases. Kidneys with highest radiation absorbed dose of 3.19E-01 mSv\/MBq were the critical organs, followed by urinary bladder wall (2.24E-01 mSv\/MBq, spleen [1.85E-01], salivary glands [1.11E-01], and liver [1.07E-01] mSv\/MBq). Red marrow dose was found to be 3.31E-02 mSv\/MBq. The mean effective dose of 3.89E-02 mSv\/MBq and effective dose of 1.95 mSv was estimated from 50 MBq (treatment planning dose) of [<jats:sup>44<\/jats:sup>Sc]Sc-PSMA-617.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>[<jats:sup>44<\/jats:sup>Sc]Sc-PSMA-617 is found to be a very promising radiopharmaceutical that can be used for pre [<jats:sup>177<\/jats:sup>Lu]Lu-PSMA-617 therapeutic dosimetric assessment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002003","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T19:21:27Z","timestamp":1519759287000},"page":"323-330","source":"Crossref","is-referenced-by-count":31,"title":["[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Ambreen","family":"Khawar","sequence":"first","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Eppard","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Phlippe","family":"Sinnes","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Roesch","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00fcrpig","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Meisenheimer","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian C.","family":"Gaertner","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Essler","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[{"name":"From the *Klinik und Poliklinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Bonn, Bonn; and \u2020Institut f\u00fcr Kernchemie, Universit\u00e4t Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20231021","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","year":"2013","journal-title":"Oncogene"},{"key":"bib2-20231021","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3747\/co.v17i0.718","article-title":"Current management of castrate-resistant prostate cancer","volume":"17","year":"2010","journal-title":"Curr Oncol"},{"key":"bib3-20231021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6061\/clinics\/2012(04)13","article-title":"Castration-resistant prostate cancer: systemic therapy in 2012","volume":"67","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"bib4-20231021","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/thno.14744","article-title":"Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent","volume":"6","year":"2016","journal-title":"Theranostics"},{"key":"bib5-20231021","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00259-015-3186-3","article-title":"Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20231021","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","article-title":"The rise of PSMA ligands for diagnosis and therapy of prostate cancer","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib7-20231021","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib8-20231021","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/thno.13348","article-title":"PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status","volume":"5","year":"2015","journal-title":"Theranostics"},{"key":"bib9-20231021","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2174\/1568026611313080008","article-title":"PET imaging in prostate cancer: focus on prostate-specific membrane antigen","volume":"13","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"bib10-20231021","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00259-015-3212-5","article-title":"68Ga-PSMA-HBED-CC PET\/CT: where molecular imaging has an edge over morphological imaging","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20231021","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","article-title":"99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib12-20231021","first-page":"1169","article-title":"Therapy of metastasized castrate-resistant prostate cancer using Lu-177 labeled DOTAGA-PSMA small molecules: first clinical results in a larger patient cohort","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib13-20231021","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","article-title":"Radiation dosimetry and first therapy results with a (124)I\/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20231021","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00259-015-3302-4","article-title":"(68)Ga-PSMA-11 dynamic PET\/CT imaging in biochemical relapse of prostate cancer","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20231021","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20231021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","article-title":"Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer","volume":"4","year":"2014","journal-title":"EJNMMI Res"},{"key":"bib17-20231021","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14737159.2016.1243057","article-title":"Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer","volume":"16","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"bib18-20231021","doi-asserted-by":"crossref","first-page":"O10","DOI":"10.1186\/1470-7330-14-S1-O10","article-title":"PSMA ligands for diagnosis and therapy of prostate cancer","volume":"14","year":"2014","journal-title":"Cancer Imaging"},{"key":"bib19-20231021","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","article-title":"Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20231021","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2967\/jnumed.114.149062","article-title":"Preclinical evaluation of 86Y-labeled inhibitors of prostate specific membrane antigen for dosimetry estimates","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib21-20231021","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","year":"2011","journal-title":"Clin Cancer Res"},{"key":"bib22-20231021","first-page":"1155","article-title":"Synthesis and evaluation of 18F-AmBF3-PSMA derivatives as PET imaging agents for prostate cancer","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib23-20231021","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"bib24-20231021","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","article-title":"Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20231021","first-page":"114","article-title":"Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","year":"2015","journal-title":"EJNMMI Res"},{"key":"bib26-20231021","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","article-title":"The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20231021","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","article-title":"Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer","volume":"43","year":"2016","journal-title":"Nucl Med Biol"},{"key":"bib28-20231021","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.115.156133","article-title":"Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib29-20231021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.nucmedbio.2016.02.002","article-title":"Clinical translation of (177)Lu-labeled PSMA-617: initial experience in prostate cancer patients","volume":"43","year":"2016","journal-title":"Nucl Med Biol"},{"key":"bib31-20231021","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib32-20231021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"bib33-20231021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1874471011205030187","article-title":"Scandium-44: benefits of a long-lived PET radionuclide available from the (44)Ti\/(44)Sc generator system","volume":"5","year":"2012","journal-title":"Curr Radiopharm"},{"key":"bib34-20231021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib35-20231021","first-page":"124","article-title":"First-in-human PET\/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44Sc-DOTATOC: a proof-of-concept study","volume":"32","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"key":"bib36-20231021","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.apradiso.2012.03.005","article-title":"Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc","volume":"70","year":"2012","journal-title":"Appl Radiat Isot"},{"key":"bib37-20231021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","article-title":"44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617\u2014preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617","volume":"7","year":"2017","journal-title":"EJNMMI Res"},{"key":"bib38-20231021","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.7150\/thno.20586","article-title":"Clinical translation and first in-human use of [44Sc]Sc-PSMA-617 for PET imaging of metastasized castrate-resistant prostate cancer","volume":"7","year":"2017","journal-title":"Theranostics"},{"key":"bib40-20231021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/02841860500244294","article-title":"Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy","volume":"44","year":"2005","journal-title":"Acta Oncol (Madr)"},{"key":"bib41-20231021","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1118\/1.1288393","article-title":"Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components","volume":"27","year":"2000","journal-title":"Med Phys"},{"key":"bib42-20231021","first-page":"126","article-title":"Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry","volume":"20","year":"2005","journal-title":"CANCER Biother Radiopharm"},{"key":"bib43-20231021","first-page":"2102","article-title":"Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body","volume":"40","year":"1999","journal-title":"J Nucl Med"},{"key":"bib44-20231021","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib45-20231021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy\u2014the Bad Berka experience","volume":"2","year":"2012","journal-title":"Theranostics"},{"key":"bib46-20231021","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.116.173757","article-title":"Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib47-20231021","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib48-20231021","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib49-20231021","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s00259-016-3424-3","article-title":"Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC\u2014a PSMA specific probe for PET imaging of prostate cancer","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib50-20231021","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib51-20231021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib52-20231021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib53-20231021","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","year":"2015","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201805000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T04:52:56Z","timestamp":1697863976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201805000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002003","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}